

# Haitao Pan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315796/publications.pdf>

Version: 2024-02-01

44  
papers

582  
citations

759233

12  
h-index

677142

22  
g-index

46  
all docs

46  
docs citations

46  
times ranked

749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Light Therapy for QoL/Depression in AYA With Cancer: A Randomized Trial. <i>Journal of Pediatric Psychology</i> , 2022, 47, 306-317.	2.1	4
2	Radiotherapy alone for pediatric patients with craniopharyngioma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 195-204.	2.9	11
3	Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. <i>Journal of Clinical Oncology</i> , 2022, 40, 335-344.	1.6	46
4	Blood DNA methylation signatures are associated with social determinants of health among survivors of childhood cancer. <i>Epigenetics</i> , 2022, , 1-15.	2.7	5
5	0500 Increased adherence to light therapy and psychosocial outcomes in adolescents and young adults with cancer. <i>Sleep</i> , 2022, 45, A221-A221.	1.1	0
6	A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. <i>Pharmaceutical Statistics</i> , 2022, 21, 1149-1166.	1.3	1
7	Feasibility and Acceptability of Light Therapy to Reduce Fatigue in Adolescents and Young Adults Receiving Cancer-Directed Therapy. <i>Behavioral Sleep Medicine</i> , 2021, 19, 492-504.	2.1	11
8	Epigenetic Age Acceleration and Chronic Health Conditions Among Adult Survivors of Childhood Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 597-605.	6.3	37
9	A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. <i>Statistics in Medicine</i> , 2021, 40, 382-402.	1.6	6
10	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2021, 27, 2442-2451.	7.0	13
11	Beginning Restorative Activities Very Early: Implementation of an Early Mobility Initiative in a Pediatric Onco-Critical Care Unit. <i>Frontiers in Oncology</i> , 2021, 11, 645716.	2.8	6
12	Persistent variations of blood DNA methylation associated with treatment exposures and risk for cardiometabolic outcomes in long-term survivors of childhood cancer in the St. Jude Lifetime Cohort. <i>Genome Medicine</i> , 2021, 13, 53.	8.2	16
13	Bayesian single-arm phase II trial designs with time-to-event endpoints. <i>Pharmaceutical Statistics</i> , 2021, 20, 1235-1248.	1.3	3
14	A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. <i>Cancer</i> , 2021, 127, 3825-3831.	4.1	18
15	Abstract 685: A social epigenomic investigation of racial disparity in pulmonary impairment among aging survivors of childhood cancer. , 2021, , .		0
16	Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age. <i>Journal of Clinical Oncology</i> , 2021, 39, 2676-2684.	1.6	4
17	A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. <i>Contemporary Clinical Trials</i> , 2021, 108, 106504.	1.8	1
18	An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 278.	3.1	1

#	ARTICLE	IF	CITATIONS
19	Spinal changes after craniospinal irradiation in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28728.	1.5	8
20	Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28617.	1.5	7
21	A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. <i>PLoS ONE</i> , 2020, 15, e0237254.	2.5	1
22	Treatment-related calvarial lesions in pediatric brain tumor survivors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28189.	1.5	1
23	Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. <i>Pharmaceutical Statistics</i> , 2020, 19, 561-582.	1.3	1
24	Keyboard design for phase I drug-combination trials. <i>Contemporary Clinical Trials</i> , 2020, 92, 105972.	1.8	18
25	OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10521-10521.	1.6	6
26	Title is missing!. , 2020, 15, e0237254.		0
27	Title is missing!. , 2020, 15, e0237254.		0
28	Title is missing!. , 2020, 15, e0237254.		0
29	Title is missing!. , 2020, 15, e0237254.		0
30	Expanded study on the risk of lymphovascular space invasion and lymph node metastasis of endocervical adenocarcinoma using Pattern Classification: a single-centre analysis of 213 cases. <i>Pathology</i> , 2019, 51, 570-578.	0.6	6
31	Comparative review of novel model-assisted designs for phase I clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 2208-2222.	1.6	57
32	Sample size determination for mediation analysis of longitudinal data. <i>BMC Medical Research Methodology</i> , 2018, 18, 32.	3.1	82
33	An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. <i>PLoS ONE</i> , 2018, 13, e0208354.	2.5	3
34	The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number. <i>Developmental Cell</i> , 2018, 47, 576-591.e8.	7.0	80
35	Effects of lymph node metastasis of thoracic esophageal squamous cell carcinoma on design of radiotherapy target volume. <i>Pakistan Journal of Medical Sciences</i> , 2018, 35, 177-182.	0.6	1
36	A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. <i>Statistics in Medicine</i> , 2017, 36, 266-279.	1.6	11

#	ARTICLE	IF	CITATIONS
37	A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2017, 66, 979-996.	1.0	40
38	Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 6763-6774.	1.8	18
39	Adaptive dose modification for phase I clinical trials. <i>Statistics in Medicine</i> , 2016, 35, 3497-3508.	1.6	12
40	Bridging continual reassessment method for phase I clinical trials in different ethnic populations. <i>Statistics in Medicine</i> , 2015, 34, 1681-1694.	1.6	23
41	The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. <i>PLoS ONE</i> , 2014, 9, e98147.	2.5	5
42	A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). <i>Clinical Trials</i> , 2014, 11, 49-59.	1.6	14
43	A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2014, 43, 254-268.	1.2	1
44	A Novel Bayesian Seamless Phase I/II Design. <i>PLoS ONE</i> , 2013, 8, e73060.	2.5	4